Lucid files for 1-for-10 reverse stock split requiring shareholder approval
Tuesday
Cantor Fitzgerald analysts have maintained their Overweight rating and $25.00 price target on ADMA Biologics (NASDAQ:ADMA), highlighting the biopharmaceutical company’s pattern of conservative revenue guidance followed by consistent upward revisions. The firm’s analysis points to ADMA’s history of surpassing its initial financial forecasts, as evidenced by the company’s performance in 2024 when it exceeded its sales guidance by 33%.
ADMA Biologics initially projected sales to be greater than $320 million in January 2024, but the actual sales for the year amounted to $426 million. Cantor Fitzgerald’s analysts believe that the company’s updated guidance, provided today, likely continues this trend of conservatism. They anticipate that the guidance does not fully account for the expected acceleration in new patient starts for ADMA’s immunoglobulin therapy, ASCENIV, and the impact of high-titer plasma supply contracts.
The analysts also noted the potential benefits of the company’s enhanced yield production process, which, if approved mid-year, could increase the production of finished intravenous immunoglobulin (IVIG) by approximately 20%. This development is particularly significant as it would contribute to the company’s growth in IVIG revenue, which has been consistently increasing quarter over quarter.
In their commentary, Cantor Fitzgerald analysts emphasized that ADMA Biologics’ IVIG revenue continues to show growth each quarter, countering any notion of stagnation. This steady rise in revenue underscores the company’s ongoing success in the biopharmaceutical market. With these factors in mind, the analysts reiterated their positive outlook on ADMA Biologics’ stock, supporting their $25.00 price target. The company maintains impressive financial metrics, including a gross profit margin of 51.48% and a healthy current ratio of 5.97. For comprehensive analysis and detailed financial metrics, investors can access ADMA’s full research report on InvestingPro, which is part of their coverage of 1,400+ US stocks.
In other recent news, ADMA Biologics reported impressive financial results for the fourth quarter of 2024, with earnings per share (EPS) of $0.46, significantly exceeding the forecasted $0.15. The company’s revenue also surpassed expectations, reaching $117.5 million compared to the anticipated $113.4 million. For the full year, ADMA Biologics’ total revenue grew by 65% to $426.5 million, with a notable improvement in its gross profit margin to 51.5%. The company’s adjusted EBITDA showed a substantial increase, reaching $164.6 million, marking a 309% rise from the previous year. In terms of future guidance, ADMA Biologics has set an ambitious revenue target of over $490 million for 2025 and expects revenue to exceed $650 million in 2026. The company is focusing on expanding its plasma collection capabilities and enhancing its production processes, which could further boost financial performance. The firm’s strategic initiatives and ongoing innovations in immunoglobulin therapy are expected to support these projections. These developments demonstrate ADMA Biologics’ robust financial health and operational efficiency, positioning it for continued growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.